Oprah Winfrey’s quit from the WeightWatchers board due to potential conflicts of interest with weight-loss medication caused the company’s shares to experience a notable decline.
Winfrey, a key figure in the company’s marketing, recently acknowledged her use of weight-loss drugs. She intends to contribute 1.4% ownership, valued at $12 million, to the National Museum of African American History and Culture.
In a statement, Winfrey expressed her commitment to continuing her advisory role with WeightWatchers and CEO Sima Sistani, focusing on recognising obesity as a chronic condition and advocating for health equity. Her departure, ending a nine-year board membership, will precede the May 2024 shareholder meeting, where she will not seek reelection.
CEO Sima Sistani acknowledged Winfrey’s significant contribution to the company and broader societal discussions on weight health, noting her upcoming absence from the board but maintaining her as a strategic advisor.
Winfrey’s exit occurs as the weight-loss industry faces transformative challenges, including the rising popularity of medications like Ozempic and Wegovy, initially developed for diabetes, leading to a national shortage. This trend poses competition to WeightWatchers, contributing to its recent financial setbacks.
